[Form 4/A] ProMIS Neurosciences Inc. Amended Insider Trading Activity
Title 19 Promis exercised purchase warrants to acquire common shares of ProMIS Neurosciences (PMN). On 07/25/2025 the reporting person exercised 119,800 Tranche A warrants, 119,800 Tranche B warrants and 119,800 Tranche C warrants, each exercised for one common share at an adjusted exercise price of $0.83518 per share (original tranche exercise prices were $2.02 for A and B, $2.50 for C). Each exercise resulted in issuance of 119,800 common shares per tranche, zero cash price reported for derivative value, and 345,316 common shares reported as beneficially owned following the transactions. The Form 4/A corrects an inadvertent prior disclosure of the exercise price. The remarks state that, based on the issuer's reported outstanding shares of 51,806,497, the reporting person’s ownership dropped below 10%.
Title 19 Promis ha esercitato warrant di acquisto per ottenere azioni ordinarie di ProMIS Neurosciences (PMN). In data 25/07/2025 il dichiarante ha esercitato 119.800 warrant Tranche A, 119.800 warrant Tranche B e 119.800 warrant Tranche C, ciascuno convertito in un’azione ordinaria al prezzo di esercizio rettificato di $0.83518 per azione (i prezzi di esercizio originali erano $2,02 per A e B e $2,50 per C). Ogni esercizio ha comportato l’emissione di 119.800 azioni ordinarie per tranche, non è stato riportato alcun corrispettivo in contanti per il valore del derivato, e dopo le operazioni risultano possedute beneficiariamente 345.316 azioni ordinarie. Il Form 4/A corregge una precedente comunicazione involontaria del prezzo di esercizio. Nelle note si precisa che, in base alle azioni in circolazione dichiarate dall’emittente pari a 51.806.497, la partecipazione del dichiarante è scesa al di sotto del 10%.
Title 19 Promis ejerció warrants de compra para adquirir acciones ordinarias de ProMIS Neurosciences (PMN). El 25/07/2025 la persona informante ejerció 119.800 warrants Tranche A, 119.800 Tranche B y 119.800 Tranche C, cada uno convertido en una acción ordinaria a un precio de ejercicio ajustado de $0.83518 por acción (los precios de ejercicio originales eran $2.02 para A y B y $2.50 para C). Cada ejercicio resultó en la emisión de 119.800 acciones ordinarias por tranche, no se reportó precio en efectivo por el valor del derivado, y tras las transacciones se informaron 345.316 acciones ordinarias en propiedad beneficiaria. El Form 4/A corrige una divulgación inadvertida previa del precio de ejercicio. En las observaciones se indica que, según las acciones en circulación reportadas por el emisor de 51.806.497, la participación del informante cayó por debajo del 10%.
Title 19 Promis는 ProMIS Neurosciences(PMN)의 보통주를 취득하기 위해 매수워런트를 행사했습니다. 2025-07-25에 보고인은 119,800개의 Tranche A 워런트, 119,800개의 Tranche B 워런트 및 119,800개의 Tranche C 워런트를 각각 행사하여 조정된 행사가격인 $0.83518 per share에 보통주 한 주로 전환했습니다(원래 트랜치 행사가격은 A·B $2.02, C $2.50). 각 행사로 트랜치당 119,800주 보통주가 발행되었고, 파생상품 가치에 대한 현금 가격은 보고되지 않았으며, 거래 후 총 345,316주 보통주를 실질적으로 보유하고 있는 것으로 보고되었습니다. Form 4/A는 이전에 실수로 공시된 행사가격을 정정한 것입니다. 비고에는 발행사가 보고한 51,806,497주를 기준으로 보고인의 지분이 10% 미만으로 하락했다고 적혀 있습니다.
Title 19 Promis a exercé des warrants d’achat pour acquérir des actions ordinaires de ProMIS Neurosciences (PMN). Le 25/07/2025, la personne déclarante a exercé 119 800 warrants de la Tranche A, 119 800 de la Tranche B et 119 800 de la Tranche C, chacun converti en une action ordinaire au prix d’exercice ajusté de $0.83518 par action (les prix d’exercice initiaux étaient de $2,02 pour A et B et $2,50 pour C). Chaque exercice a entraîné l’émission de 119 800 actions ordinaires par tranche, aucun prix en espèces n’a été déclaré pour la valeur du produit dérivé, et 345 316 actions ordinaires ont été déclarées comme détenues effectivement après les opérations. Le formulaire 4/A corrige une divulgation antérieure involontaire du prix d’exercice. Les remarques indiquent que, sur la base des actions en circulation déclarées par l’émetteur de 51 806 497, la participation du déclarant est passée en dessous de 10%.
Title 19 Promis hat Kauf-Warrants ausgeübt, um Stammaktien von ProMIS Neurosciences (PMN) zu erwerben. Am 25.07.2025 übte die meldende Person 119.800 Tranche-A-Warrants, 119.800 Tranche-B-Warrants und 119.800 Tranche-C-Warrants aus, jeweils zum Umtausch in eine Stammaktie zu einem bereinigten Ausübungspreis von $0.83518 pro Aktie (ursprüngliche Ausübungspreise: A und B $2,02, C $2,50). Jede Ausübung führte zur Ausgabe von 119.800 Stammaktien pro Tranche, es wurde kein Bargeldbetrag für den Derivatewert gemeldet, und nach den Transaktionen wurden 345.316 Stammaktien als wirtschaftlich gehalten gemeldet. Das Formular 4/A korrigiert eine versehentliche frühere Angabe des Ausübungspreises. In den Bemerkungen heißt es, dass die Beteiligung der meldenden Person anhand der vom Emittenten berichteten ausstehenden Aktien von 51.806.497 unter 10% gefallen ist.
- Corrected disclosure of the exercise price from $0.83158 to $0.83518, improving filing accuracy
- Issuer-accepted exercise achieved, converting warrants into common shares and clarifying beneficial ownership
- Reporting person’s ownership dropped below 10% based on issuer's reported 51,806,497 outstanding shares
- Initial filing contained an incorrect exercise price, requiring an amendment to correct material transaction detail
Insights
TL;DR Insider exercised warrants materially below original strike prices, increasing common shares outstanding and correcting a prior pricing error.
The exercise of 359,400 warrants (119,800 per tranche) at an accepted price of $0.83518 materially changes the reporting person’s immediate share count while reflecting amendment-level housekeeping to correct the disclosed exercise price. This is an issuer-accepted private exercise arrangement reducing the effective price paid versus original tranche strikes; the filing notes resulting beneficial ownership of 345,316 shares and that ownership fell below 10% using the issuer's stated outstanding share count of 51,806,497. For investors, the transaction is primarily a change in ownership composition and disclosure accuracy rather than a direct statement about operational performance.
TL;DR Amendment clarifies exercise price and reports changes to insider ownership percentage; governance disclosure corrected.
The Form 4/A aligns insider reporting with the issuer-approved exercise terms and corrects a numeric error in the initial filing. Accurate disclosure of exercise prices and resultant ownership percentages is important for compliance and market transparency. The remark that ownership fell below 10%—based on the issuer's reported outstanding shares—highlights the importance of timely issuer share counts in Section 16 calculations. This amendment addresses disclosure integrity rather than alleging misconduct.
Title 19 Promis ha esercitato warrant di acquisto per ottenere azioni ordinarie di ProMIS Neurosciences (PMN). In data 25/07/2025 il dichiarante ha esercitato 119.800 warrant Tranche A, 119.800 warrant Tranche B e 119.800 warrant Tranche C, ciascuno convertito in un’azione ordinaria al prezzo di esercizio rettificato di $0.83518 per azione (i prezzi di esercizio originali erano $2,02 per A e B e $2,50 per C). Ogni esercizio ha comportato l’emissione di 119.800 azioni ordinarie per tranche, non è stato riportato alcun corrispettivo in contanti per il valore del derivato, e dopo le operazioni risultano possedute beneficiariamente 345.316 azioni ordinarie. Il Form 4/A corregge una precedente comunicazione involontaria del prezzo di esercizio. Nelle note si precisa che, in base alle azioni in circolazione dichiarate dall’emittente pari a 51.806.497, la partecipazione del dichiarante è scesa al di sotto del 10%.
Title 19 Promis ejerció warrants de compra para adquirir acciones ordinarias de ProMIS Neurosciences (PMN). El 25/07/2025 la persona informante ejerció 119.800 warrants Tranche A, 119.800 Tranche B y 119.800 Tranche C, cada uno convertido en una acción ordinaria a un precio de ejercicio ajustado de $0.83518 por acción (los precios de ejercicio originales eran $2.02 para A y B y $2.50 para C). Cada ejercicio resultó en la emisión de 119.800 acciones ordinarias por tranche, no se reportó precio en efectivo por el valor del derivado, y tras las transacciones se informaron 345.316 acciones ordinarias en propiedad beneficiaria. El Form 4/A corrige una divulgación inadvertida previa del precio de ejercicio. En las observaciones se indica que, según las acciones en circulación reportadas por el emisor de 51.806.497, la participación del informante cayó por debajo del 10%.
Title 19 Promis는 ProMIS Neurosciences(PMN)의 보통주를 취득하기 위해 매수워런트를 행사했습니다. 2025-07-25에 보고인은 119,800개의 Tranche A 워런트, 119,800개의 Tranche B 워런트 및 119,800개의 Tranche C 워런트를 각각 행사하여 조정된 행사가격인 $0.83518 per share에 보통주 한 주로 전환했습니다(원래 트랜치 행사가격은 A·B $2.02, C $2.50). 각 행사로 트랜치당 119,800주 보통주가 발행되었고, 파생상품 가치에 대한 현금 가격은 보고되지 않았으며, 거래 후 총 345,316주 보통주를 실질적으로 보유하고 있는 것으로 보고되었습니다. Form 4/A는 이전에 실수로 공시된 행사가격을 정정한 것입니다. 비고에는 발행사가 보고한 51,806,497주를 기준으로 보고인의 지분이 10% 미만으로 하락했다고 적혀 있습니다.
Title 19 Promis a exercé des warrants d’achat pour acquérir des actions ordinaires de ProMIS Neurosciences (PMN). Le 25/07/2025, la personne déclarante a exercé 119 800 warrants de la Tranche A, 119 800 de la Tranche B et 119 800 de la Tranche C, chacun converti en une action ordinaire au prix d’exercice ajusté de $0.83518 par action (les prix d’exercice initiaux étaient de $2,02 pour A et B et $2,50 pour C). Chaque exercice a entraîné l’émission de 119 800 actions ordinaires par tranche, aucun prix en espèces n’a été déclaré pour la valeur du produit dérivé, et 345 316 actions ordinaires ont été déclarées comme détenues effectivement après les opérations. Le formulaire 4/A corrige une divulgation antérieure involontaire du prix d’exercice. Les remarques indiquent que, sur la base des actions en circulation déclarées par l’émetteur de 51 806 497, la participation du déclarant est passée en dessous de 10%.
Title 19 Promis hat Kauf-Warrants ausgeübt, um Stammaktien von ProMIS Neurosciences (PMN) zu erwerben. Am 25.07.2025 übte die meldende Person 119.800 Tranche-A-Warrants, 119.800 Tranche-B-Warrants und 119.800 Tranche-C-Warrants aus, jeweils zum Umtausch in eine Stammaktie zu einem bereinigten Ausübungspreis von $0.83518 pro Aktie (ursprüngliche Ausübungspreise: A und B $2,02, C $2,50). Jede Ausübung führte zur Ausgabe von 119.800 Stammaktien pro Tranche, es wurde kein Bargeldbetrag für den Derivatewert gemeldet, und nach den Transaktionen wurden 345.316 Stammaktien als wirtschaftlich gehalten gemeldet. Das Formular 4/A korrigiert eine versehentliche frühere Angabe des Ausübungspreises. In den Bemerkungen heißt es, dass die Beteiligung der meldenden Person anhand der vom Emittenten berichteten ausstehenden Aktien von 51.806.497 unter 10% gefallen ist.
FAQ
What warrants did Title 19 Promis exercise in the Form 4/A for PMN?
At what price were the PMN warrants exercised?
How many common shares did the reporting person beneficially own after these transactions?
Did the filing amend any previously reported information?
Did the reporting person remain a 10% owner after the amendment?
